AOD-9604

Background

AOD-9604 is a synthetic peptide derived from the C-terminal region (amino acids 177–191) of human growth hormone (hGH), modified to enhance metabolic effects while reducing classical growth hormone–related activity.[2][4] It is often described as a modified GH fragment 177–191 and has been investigated primarily for potential anti-obesity and metabolic indications.[4][5] AOD-9604 was originally developed by Metabolic Pharmaceuticals (Australia) as an orally active or injectable peptide intended to mimic the fat-reducing effects of hGH without stimulating insulin-like growth factor-1 (IGF-1)–mediated growth pathways.[4][5]

Early preclinical work focused on rodent models of obesity and metabolic syndrome, reporting increased lipolysis, reduced adiposity, and improved lipid profiles with minimal effects on linear growth or IGF-1 levels.[4][5] Subsequent human phase 1 and phase 2 studies explored safety, pharmacokinetics, and short-term weight or fat mass changes in overweight and obese adults.[4][5][6] While these studies suggested a favorable short-term safety profile, efficacy signals for clinically meaningful weight loss were limited and inconsistent, and development for obesity was not successfully completed.[4][5]

Despite the lack of regulatory approval as a drug, AOD-9604 has appeared in commercial wellness and sports medicine markets, frequently promoted off-label for weight management and body composition modification. This use is not supported by robust, large, controlled trials and exists outside formal regulatory authorization.[2][4] AOD-9604 has also been subject to regulatory scrutiny in the context of sports anti-doping, where it has been considered a non-approved peptide with potential performance- or body-composition–modifying properties.[2]

Mechanism of action

AOD-9604 is a 15–amino acid peptide corresponding to the C-terminal 177–191 fragment of hGH with additional modifications that appear to confer resistance to enzymatic degradation and alter receptor interactions.[4][5] Unlike full-length hGH, which signals through the growth hormone receptor (GHR) to activate the JAK2–STAT5 pathway and stimulate hepatic IGF-1 production, AOD-9604 does not meaningfully raise circulating IGF-1 or promote somatic growth in preclinical models or short-term human studies.[4][5]

Mechanistically, AOD-9604 has been reported to stimulate lipolysis and inhibit lipogenesis in adipocytes, acting in a manner similar to the native 177–191 fragment of hGH but without broader anabolic effects.[4][5] In vitro data suggest enhancement of hormone-sensitive lipase activity and modulation of lipid metabolism genes, leading to increased breakdown of triglycerides and reduced de novo fat storage.[4][5] Some studies indicate that these effects may be mediated indirectly by cAMP and downstream kinase signaling rather than through classical GHR activation, although the precise receptor target or binding partners for AOD-9604 remain incompletely defined.[4]

Animal studies in obese rodents showed decreased body fat and improved lipid profiles without changes in longitudinal bone growth, organ hypertrophy, or insulin resistance, supporting a dissociation between fat-metabolic actions and growth-promoting or diabetogenic effects typical of full-length hGH.[4][5] In human studies, AOD-9604 administration did not significantly alter IGF-1, glucose, or insulin levels over short durations, consistent with a mechanism focused on adipocyte lipid turnover rather than systemic growth axis stimulation.[5][6]

Evidence summary

Preclinical evidence

1. Rodent obesity models
   Studies in diet-induced obese rodents reported that AOD-9604 increased lipolysis, reduced body fat mass, and improved serum lipid profiles, with minimal effect on body length or organ size.[4][5] Dosing regimens in these models included daily injections over several weeks, with reported reductions in white adipose tissue mass and no significant changes in IGF-1 levels.[4][5]

2. In vitro adipocyte studies
   In cultured adipocytes, the GH 177–191 fragment and AOD-9604 analogues showed increased lipolysis and decreased lipogenesis, associated with increased glycerol release and altered expression of lipid metabolism enzymes.[4][5] These effects occurred without the full spectrum of GHR-mediated gene expression changes seen with intact hGH.[4]

Overall, preclinical data consistently indicate fat-modulating effects with limited growth-promoting activity, but detailed receptor pharmacology remains incompletely characterized and many reports are from company-sponsored or limited-circulation sources.[4][5]

Clinical evidence

Published peer-reviewed data on AOD-9604 in humans are limited and largely consist of early-phase trials in obesity and metabolic risk. Sample sizes are modest, study durations short, and findings on efficacy are mixed.

1. Phase 1 safety and pharmacokinetics
   A first-in-human, randomized, placebo-controlled phase 1 study in healthy volunteers (sponsor: Metabolic Pharmaceuticals) evaluated single and multiple ascending doses of AOD-9604 (oral and/or injectable forms).[5] The study reported that AOD-9604 was generally well tolerated across the tested dose ranges, with adverse events comparable to placebo and no clinically relevant changes in IGF-1, glucose, insulin, or routine safety laboratories.[5] Sample sizes in phase 1 cohorts were small (typical of dose-escalation designs, often 6–10 active vs 2–4 placebo per cohort), and the trial was not powered for efficacy.[5]

2. Phase 2 obesity studies
   Phase 2 studies in overweight or obese adults investigated daily AOD-9604 administration for several weeks to months, with endpoints including body weight, fat mass, waist circumference, and metabolic markers.[4][5][6] Reported sample sizes ranged from dozens to low hundreds of participants in multicenter, randomized, placebo-controlled designs.[5][6]

   Across these trials, AOD-9604 showed:

   • A generally benign short-term safety profile, with adverse events similar in frequency and severity to placebo.[5][6]
   • Inconsistent or modest effects on weight loss and body fat reduction, often not statistically significant compared with placebo for primary endpoints.[5][6]
   • No significant increases in IGF-1 or evidence of fluid retention or glucose intolerance typically associated with hGH therapy.[5]

3. Other indications
   Limited exploratory work has been discussed in orthopaedic and sports medicine contexts, where AOD-9604 is sometimes categorized among growth hormone–related peptides considered for musculoskeletal recovery, although explicit clinical trials in these indications are not documented.[2] A recent orthopaedic review mentions AOD-9604 among GH secretagogues and related peptides used in practice but notes a general lack of rigorous clinical trials supporting their use in musculoskeletal conditions.[2]

Overall, there is early clinical evidence demonstrating short-term safety at studied doses, but efficacy for obesity or other indications remains unproven and unsupported by large, confirmatory phase 3 trials.[4][5][6]

Clinical and research uses

Investigational and off-label contexts

• Obesity and weight management: AOD-9604 has been investigated as an anti-obesity agent aimed at enhancing fat loss and improving lipid profiles without typical GH side effects.[4][5][6] Clinical data to date do not demonstrate robust, reproducible weight-loss efficacy.
• Metabolic risk modulation: Some trials assessed changes in triglycerides, cholesterol, and other metabolic markers, but results have been modest and variable.[5][6]
• Sports and orthopaedics: AOD-9604 is sometimes used in sports and orthopaedic practice settings as a putative body-composition or recovery aid; however, this use is based largely on theoretical mechanisms and extrapolation rather than high-quality clinical evidence.[2]

No major guideline or consensus body currently endorses AOD-9604 for any therapeutic indication. Its use in clinical or wellness settings is off-label and not grounded in robust, late-phase trial data.[4][5][6]

Dosing context

Published information and sponsor communications describe AOD-9604 being administered in clinical studies as daily doses, typically via oral formulations or subcutaneous injection, over periods ranging from several weeks to several months.[4][5][6] Exact dose levels have included multiple fixed-dose arms, often spanning low to moderate milligram or microgram-per-kilogram ranges, but detailed numeric dosing and formulation data are not consistently available in public, peer-reviewed sources.[4][5]

In obesity phase 2 trials, participants received once-daily dosing, with some studies exploring different strengths to evaluate dose–response relationships for weight and adiposity endpoints.[5][6] No standardized or approved dosing regimen exists, and all dosing information should be interpreted strictly as historical trial design rather than as therapeutic guidance.

Because AOD-9604 is not approved as a medicinal product, any dosing used in wellness or sports contexts is effectively experimental and outside of established regulatory frameworks.[4][5]

Safety profile

General tolerability

Phase 1 and phase 2 clinical studies reported that AOD-9604 was generally well tolerated over short treatment durations, with an adverse event profile similar to placebo.[5][6] Commonly reported events included mild gastrointestinal symptoms, headache, and injection-site reactions (for parenteral formulations), none of which showed clear dose-limiting patterns in early studies.[5]

Endocrine and metabolic effects

A key rationale for AOD-9604 development was to avoid the IGF-1 elevation and fluid retention associated with full-length hGH therapy. In human trials:

• No significant increases in circulating IGF-1 were observed.[5]
• No consistent changes in fasting glucose, insulin, or HbA1c were reported over study periods.[5][6]
• No evidence of accelerated linear growth or acromegaloid changes was seen in adult participants.[5]

However, long-term effects on growth, neoplasia risk, or metabolic health have not been systematically studied.

Serious adverse events and long-term data

No clear signal for serious drug-related adverse events has been reported in early-phase studies, but follow-up durations were limited, and sample sizes were modest.[5][6] There is insufficient evidence to evaluate:

• Carcinogenicity or tumor-promoting effects
• Impacts on fertility or pregnancy
• Long-term cardiovascular outcomes
• Pediatric safety

Contraindications and cautions (theoretical/indirect)

Due to its relationship to hGH pathways, theoretical caution is often advised in patients with:

• Active malignancy or history of cancer, where growth-related signaling could, in principle, be relevant
• Proliferative diabetic retinopathy or other conditions sensitive to growth factors

These cautions are extrapolated from hGH pharmacology and general principles rather than specific AOD-9604 data.[4][5] Robust, indication-specific contraindication profiles have not been defined.

Regulatory status

United States

AOD-9604 is not approved by the U.S. Food and Drug Administration (FDA) as a drug for any indication. It does not appear among peptide drugs listed in recent comprehensive FDA peptide/oligonucleotide approval reviews, which catalog currently approved peptide therapeutics.[13] There is no publicly available FDA New Drug Application (NDA) approval for AOD-9604, and its use in clinical practice is therefore off-label and unapproved.

AOD-9604 has also drawn attention in the context of sports anti-doping, where agencies have indicated that it is not an approved therapeutic and may be treated as a prohibited peptide when used to modify body composition or performance, although specific categorizations can evolve over time.[2]

Europe and other regions

There is no evidence of European Medicines Agency (EMA) approval of AOD-9604 as a medicinal product, and it is not listed among approved peptide-based drugs in contemporary regulatory reviews.[13] Any use within the EU would therefore occur outside of formal medicinal product authorization.

Research and compounding context

AOD-9604 may be available via research supply channels or compounding pharmacies in some jurisdictions, but such availability does not equate to regulatory approval. Its status can vary by country and over time, and in many settings it would be considered an unlicensed or experimental peptide with no established quality, safety, or efficacy standards.[4][5]

Given the absence of formal approval and limited clinical data, the current overall assessment is that AOD-9604 remains an investigational peptide with early-clinical evidence only, and its routine therapeutic use is not supported by regulatory agencies or high-level clinical guidelines.[4][5][6]